Analgesia and curative effect of pamidronate disodium combined with chemotherapy on elderly patients with advanced metastatic bone cancer

Abstract

The curative effect and adverse reactions of pamidronate disodium in elderly patients with advanced metastatic bone cancer were evaluated. A total of 160 elderly patients with advanced metastatic bone cancer admitted to Affiliated Hospital of Nantong University from February 2012 to January 2015, were divided into the chemotherapy group (n=60) that received routine therapy and the pamidronate disodium group (n=100) that received pamidronate disodium therapy based on the chemotherapy. Pain relief, analgesic time, analgesic duration and side effects were compared between the two groups after treatment. The effect of pain relief in the pamidronate disodium group was significantly higher than that in the chemotherapy group (P<0.001). The total effective rate of the pamidronate disodium group was significantly higher than that of the chemotherapy group (P<0.001). The analgesic onset time in the pamidronate disodium group was earlier than in the chemotherapy group (P<0.001). The analgesic duration in the pamidronate disodium group was longer than that in the chemotherapy group (P<0.001). The incidence of adverse reactions and complications after treatment in the pamidronate disodium group was significantly less than that in the chemotherapy group (P<0.001). The results indicated that pamidronate disodium is effective in the treatment of elderly patients with advanced metastatic bone cancer and patients are less prone to adverse reactions, complications and pain, which is worthy of clinical application.

Prostate cancer bone metastases biology and clinical management (Review)

“…For example, pamidronate disodium has been investigated for its utility in treating skeletal metastases progression and the associated bone pain experienced by patients. However, results have been largely inconclusive and show no notable significant improvement to disease or symptom management ( 111 , 112 ). This may be a result of pamidronate disodium not being as potent as some of the more recently developed bisphosphate treatments available in the clinic, such as zoledronic acid ( 113 ).…”

A Systematic Review and Meta Analysis of Non-Randomized Interventional Studies on the Pamidronate Treatment Efficacy for Patients with Bone Fibrous Dysplasia

“…10 This treatment also has an initial pain-relieving effect from its direct analgesic properties, but the exact pain-relieving mechanism is still being searched for. 11 The use of pamidronate contributes to the reduction of serum alkaline phosphatase (SAP). SAP level is a vital laboratory finding correlated with osteoblastic activity which is often applied as an important prognostic marker for FD and bone-related malignant tumors, such as osteosarcoma.…”